Marketing devices for disease management is opportunity in managed care setting.
This article was originally published in The Gray Sheet
Executive Summary
MEDICAL EQUIPMENT "PACKAGES" FOR DISEASE-STATE MANAGEMENT offer a growth opportunity for manufacturers in the changing health care environment, Blue Cross of California Executive Vice President Mark Weinberg said March 20 at the Health Industry Manufacturers Association annual meeting. Noting that his company has "literally a series of disease-specific policies that have their own cost contributions, their own protocols and their own basic methods of receiving funding from us," Weinberg said that disease-state management provides manufacturers a "great opportunity for someone bringing together all of" the technology needed to treat that disease.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.